Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of MK-0634 in postmenopausal women with overactive bladder
2005-004499-19Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-0634 in overactive bladder (OAB) (4 arms), sponsored by Merck & Co. Primary endpoint: Dose-related reduction in average daily micturitions at Week 8. Started Oct 2005; status: completed.
02
Drugs
MK-0634
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-004499-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004499-19.